VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | Targeted therapy for Ph-like ALL

Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, reviews a variety of off-label therapeutic strategies for patients with Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL), including the application of tyrosine kinase (TK) inhibitors-based strategies in combination with chemotherapy and how specific genetic mutations within Ph-like ALL may be targeted by specific TK inhibitors.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter